ECSP088179A - Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos - Google Patents

Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos

Info

Publication number
ECSP088179A
ECSP088179A EC2008008179A ECSP088179A ECSP088179A EC SP088179 A ECSP088179 A EC SP088179A EC 2008008179 A EC2008008179 A EC 2008008179A EC SP088179 A ECSP088179 A EC SP088179A EC SP088179 A ECSP088179 A EC SP088179A
Authority
EC
Ecuador
Prior art keywords
formula
group
phenyl
alkyl
treatment
Prior art date
Application number
EC2008008179A
Other languages
English (en)
Inventor
Boyu Zhao
Roy E Twyman
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37637734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP088179A publication Critical patent/ECSP088179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invención se dirige a métodos para proveer neuroprotección que comprenden administrar a un sujeto que necesita de la misma una cantidad terapéuticamente efectiva de un compuesto seleccionado a partir del grupo que consiste de la fórmula (I) y de la fórmula (II), o una sal o éster farmacéuticamente aceptable del mismo,:Fórmula (I) Fórmula (II)en donde el fenilo está sustituido en X con uno a cinco átomos de halógeno seleccionados a partir del grupo que consiste de flúor, cloro, bromo y yodo; y, R1, R2, R3, R4, R5 y R6 son independientemente seleccionados a partir del grupo que consiste de hidrógeno y alquilo de C1-C4; en donde alquilo de C1-C4 está opcionalmente sustituido con fenilo (en donde fenilo está opcionalmente sustituido con sustituyentes independientemente seleccionados a partir del grupo que consiste de halógeno, alquilo de C1-C4, alcoxi de C1-C4, amino, nitro y ciano).
EC2008008179A 2005-07-12 2008-02-12 Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos ECSP088179A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69840305P 2005-07-12 2005-07-12

Publications (1)

Publication Number Publication Date
ECSP088179A true ECSP088179A (es) 2008-03-26

Family

ID=37637734

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008179A ECSP088179A (es) 2005-07-12 2008-02-12 Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos

Country Status (18)

Country Link
US (2) US20070021500A1 (es)
EP (1) EP1917009A2 (es)
JP (1) JP2009501224A (es)
KR (1) KR20080031951A (es)
CN (1) CN101287459A (es)
AR (1) AR054551A1 (es)
AU (1) AU2006269381A1 (es)
BR (1) BRPI0613006A2 (es)
CA (1) CA2615129A1 (es)
CR (1) CR9721A (es)
EA (1) EA200800294A1 (es)
EC (1) ECSP088179A (es)
IL (1) IL188729A0 (es)
NI (1) NI200800008A (es)
NO (1) NO20080738L (es)
TW (1) TW200800158A (es)
WO (1) WO2007008562A2 (es)
ZA (1) ZA200801401B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7962215B2 (en) 2004-07-23 2011-06-14 Synapse Biomedical, Inc. Ventilatory assist system and methods to improve respiratory function
CN101272776B (zh) * 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
US9050005B2 (en) 2005-08-25 2015-06-09 Synapse Biomedical, Inc. Method and apparatus for transgastric neurostimulation
US20080097153A1 (en) * 2006-08-24 2008-04-24 Ignagni Anthony R Method and apparatus for grasping an abdominal wall
KR20090076958A (ko) * 2006-10-06 2009-07-13 얀센 파마슈티카 엔.브이. 신규 (ｓ)-(＋)-2-(2-클로로페닐)-2-하이드록시-에틸 카바메이트 결정
US9079016B2 (en) * 2007-02-05 2015-07-14 Synapse Biomedical, Inc. Removable intramuscular electrode
WO2008144578A1 (en) * 2007-05-17 2008-11-27 Synapse Biomedical, Inc. Devices and methods for assessing motor point electromyogram as a biomarker
US8428726B2 (en) 2007-10-30 2013-04-23 Synapse Biomedical, Inc. Device and method of neuromodulation to effect a functionally restorative adaption of the neuromuscular system
US8478412B2 (en) * 2007-10-30 2013-07-02 Synapse Biomedical, Inc. Method of improving sleep disordered breathing
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
KR101418061B1 (ko) * 2012-09-28 2014-07-10 한국과학기술연구원 성상교세포의 글루타메이트 방출 기작
KR101758543B1 (ko) * 2013-03-12 2017-07-14 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 신경가스에 의한 질환의 예방 또는 치료용 조성물
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CA3016253C (en) * 2016-02-29 2020-12-29 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds, processes for preparing them and their uses
US11471683B2 (en) 2019-01-29 2022-10-18 Synapse Biomedical, Inc. Systems and methods for treating sleep apnea using neuromodulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
SK286621B6 (sk) * 1999-08-20 2009-02-05 Ortho-Mcneil Pharmaceutical, Inc. Farmaceutický prostriedok obsahujúci kombináciu tramadolového materiálu a antikonvulzívneho činidla, táto kombinácia a jej použitie na výrobu liečiva
CN1235579C (zh) * 2001-02-27 2006-01-11 奥索-麦克尼尔药品公司 用于预防或治疗神经变性疾病的氨基甲酸酯化合物
US20060194873A1 (en) * 2004-09-16 2006-08-31 Choi Yong M Methods of treating epileptogenesis and epilepsy
PE20070325A1 (es) * 2005-06-29 2007-05-12 Alza Corp Formas de dosificacion oral que comprenden compuestos derivados de carbamato

Also Published As

Publication number Publication date
IL188729A0 (en) 2008-11-03
TW200800158A (en) 2008-01-01
CR9721A (es) 2008-11-24
US20090137652A1 (en) 2009-05-28
KR20080031951A (ko) 2008-04-11
CA2615129A1 (en) 2007-01-18
EP1917009A2 (en) 2008-05-07
US20070021500A1 (en) 2007-01-25
WO2007008562A2 (en) 2007-01-18
CN101287459A (zh) 2008-10-15
WO2007008562A3 (en) 2007-08-16
JP2009501224A (ja) 2009-01-15
NI200800008A (es) 2010-11-25
AU2006269381A1 (en) 2007-01-18
BRPI0613006A2 (pt) 2010-12-14
AR054551A1 (es) 2007-06-27
EA200800294A1 (ru) 2008-06-30
NO20080738L (no) 2008-04-10
ZA200801401B (en) 2009-08-26

Similar Documents

Publication Publication Date Title
ECSP088179A (es) Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos
ECSP088172A (es) Metodos para tratar la epileptogenesis
EA200700642A1 (ru) Способы лечения эпилептогенеза и эпилепсии
CO6180427A2 (es) Tratamiento de los trastornos generalizados del desarrollo
AR054524A1 (es) Metodos y formas de dosificacion para reducir los efectos secundarios de compuestos de carbamato
EA200800422A1 (ru) Способы лечения заболеваний, обусловленных химическими веществами
EA200701536A1 (ru) Способы контроля интервала qt
ECSP077395A (es) Compuesto de carbamato para utilizar en el tratamiento de padecimientos neurodegenerativos
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
CO6180505A2 (es) Metodos para el tratamiento de transtornos cocleares y vestibulares
YU67803A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju bipolarnih poremaćaja
CO6160292A2 (es) Metodos de tratamiento de transtornos de comportamiento perturbador 877
UY29158A1 (es) Metodos de tratamiento de la epileptogénesis y la epilepsia
MY136733A (en) Carbamate compounds for use in preventing or treating psychotic disorders
CR9766A (es) Metodos para el tratamiento de trastornos relacionados con sustancias
AR035757A1 (es) Uso de carbamatos para la fabricacion de medicamentos para prevenir o tratar un trastorno bipolar
CY1110672T1 (el) Χρηση των 2- φαινυλ-1,2-αιθανοδιολης- (δι) καρβαμικων για θεραπεια επιληπτογενεσης
AR033428A1 (es) Compuestos carbamatos para su uso en la prevencion o tratamiento de trastornos bipolares